Exagen raises funds for gene-based prognostics
This article was originally published in Clinica
Executive Summary
Exagen Diagnostics, of Albuquerque, New Mexico, has raised $5.4m in a series A financing led by healthcare private equity group Tullis-Dickerson. The funds will help the company develop gene-based tests that predict a patient's reaction to medicines.